ライフサイエンスコーパス: Chagas' disease

1 nfirmed chronic Trypanosoma cruzi infection (Chagas disease).

2 tion have been used to study heart damage in Chagas disease.

3 in these areas that aid in the management of Chagas disease.

4 Trypanosoma cruzi, the parasite that causes Chagas disease.

5 yme, can cure the acute and chronic forms of Chagas disease.

6 of Trypanosoma cruzi, the etiologic agent of Chagas disease.

7 ites in the hearts of those who succumbed to Chagas disease.

8 liant squaramides as candidates for treating Chagas disease.

9 te Trypanosoma cruzi, the causative agent of Chagas disease.

10 o capture the TcVac2-induced protection from Chagas disease.

11 Trypanosoma cruzi is the etiologic agent of Chagas disease.

12 the clinical and epidemiological aspects of Chagas disease.

13 factor to prevent myocardial damage in human Chagas disease.

14 ty on parasitemia in a murine model of acute Chagas disease.

15 Trypanosoma cruzi is the causative agent of Chagas disease.

16 vidence of its effectiveness against chronic Chagas disease.

17 nsible for human African trypanosomiasis and Chagas disease.

18 an Trypanosoma cruzi, the causative agent of Chagas disease.

19 ore attention and efforts towards control of Chagas disease.

20 an Trypanosoma cruzi, the causative agent of Chagas disease.

21 st Trypanosoma cruzi, the causative agent of Chagas disease.

22 logy in both the acute and chronic phases of Chagas disease.

23 rocycles can lead to useful cidal agents for Chagas disease.

24 an adjuvant therapy for treatment of chronic Chagas disease.

25 cellular parasite and the causative agent of Chagas disease.

26 e an important factor in the pathogenesis of Chagas disease.

27 merica and often leads to the development of Chagas disease.

28 leads for the development of drugs to treat Chagas disease.

29 pathomechanism of sustained inflammation in Chagas disease.

30 drugs to develop an efficient treatment for Chagas disease.

31 ction and oxidative stress may contribute to Chagas disease.

32 r efficacy studies in a mouse model of acute Chagas disease.

33 luding Trypanosoma cruzi, the agent of human Chagas disease.

34 4.4%) patients, 2 of them in early stages of Chagas disease.

35 and is efficacious in a mouse model of acute Chagas disease.

36 African sleeping sickness, leishmaniasis and Chagas disease.

37 tential to lead to new chemotherapeutics for Chagas disease.

38 onsible for prominent systemic congestion in Chagas disease.

39 tion, management, and etiologic treatment of Chagas disease.

40 of multinational control initiatives against Chagas disease.

41 refore an important target cell during acute Chagas disease.

42 kinetoplastid protozoan pathogen that causes Chagas disease.

43 e whole-blood transcriptome of patients with Chagas disease.

44 erminant in transmission and pathogenesis of Chagas disease.

45 om Trypanosoma cruzi, the causative agent of Chagas disease.

46 hen trying to understand the pathogenesis of Chagas disease.

47 f digestive pathologies of clinical forms of Chagas disease.

48 omen of childbearing age prevents congenital Chagas disease.

49 and CD1d by CD14(+) cells from patients with Chagas disease.

50 ac pathology in a BALB/c mouse model of live Chagas disease.

51 m of human African trypanosomiasis (HAT) and Chagas disease.

52 worse ventricular function in patients with Chagas disease.

53 Benznidazole is the drug of choice for Chagas disease.

54 Trypanosoma cruzi, the etiological agent of Chagas disease.

55 kg/day for 60 days in 30 adults with chronic Chagas disease.

56 ypanosomal activity in patients with chronic Chagas' disease.

57 nd more effective drugs for the treatment of Chagas' disease.

58 istry efforts to develop drug candidates for Chagas' disease.

59 dioprotective role during the acute stage of Chagas' disease.

60 an Trypanosoma cruzi, the causative agent of Chagas' disease.

61 utaneous infection in a mouse model of acute Chagas' disease.

62 e events in nervous tissues of patients with Chagas' disease.

63 Trypanosoma cruzi is the etiologic agent of Chagas' disease.

64 nctions and be important in the pathology of Chagas' disease.

65 present in the sera of patients with chronic Chagas' disease.

66 re released into the plasma of patients with Chagas' disease.

67 contribute to increased protein nitration in Chagas' disease.

68 stress may be important in the pathology of Chagas' disease.

69 odified proteins may be useful biomarkers of Chagas' disease.

70 st Trypanosoma cruzi, the causative agent of Chagas' disease.

71 tochondrial decay and oxidative pathology in Chagas' disease.

72 of mitochondrial functional decline in acute Chagas' disease.

73 of Trypanosoma cruzi, the causative agent of Chagas' disease.

74 ssion of parasite burden in a mouse model of Chagas' disease.

75 in Trypanosoma cruzi, the causative agent of Chagas' disease.

76 were uninfected control patients and 120 had Chagas disease (1 group had asymptomatic disease, and 2

77 atients with indeterminate/digestive form of Chagas disease (35.7%) compared with those with Chagas c

78 83%), 38 of 88 leishmaniasis (43%), 18 of 31 Chagas disease (58%), 7 of 28 SA blastomycosis (25%), an

79 0 million people in Latin America and causes Chagas disease, a chronic inflammatory disease with fata

80 cruzi parasites are the causative agents of Chagas disease, a leading infectious form of heart failu

81 For Chagas disease, a more extensive validation of the test

82 rypanosoma cruzi is the etiological agent of Chagas disease, a neglected and emerging tropical diseas

83 Chagas disease, a neglected tropical disease discovered

84 zi is a protozoan parasite that causes human Chagas' disease, a leading source of congestive heart fa

85 Trypanosoma cruzi (the etiological agent of Chagas disease) adapting via trade-off among three diffe

86 The most threatening trypanosomiasis is Chagas disease, affecting up to 12 million people in the

87 suicide, liver cancer, diabetes, cirrhosis, Chagas disease, African trypanosomiasis, melanoma, and o

88 asite-derived protein, PDNF, produced by the Chagas' disease agent Trypanosoma cruzi, functionally mi

89 t patients diagnosed in the chronic phase of Chagas disease already exhibit heart involvement, and th

90 Trypanosoma cruzi causes Chagas disease (American trypanosomiasis), which threate

91 gnoses included schistosomiasis (Africa) and Chagas disease (Americas).

92 There is a high prevalence of Chagas disease among Latin American immigrants diagnosed

93 ct physiology, but also is a major vector of Chagas disease, an illness that affects approximately se

94 runcated into fragments that are specific to Chagas disease and have the potential to be used as diag

95 BIA platform for in situ diagnosis of human (Chagas disease and human brucellosis) and animal (bovine

96 osoma cruzi, which is the causative agent of Chagas disease and is a promising target for the develop

97 nt and severe manifestation of human chronic Chagas disease and is characterized by heart failure, ve

98 Millions afflicted with Chagas disease and other disorders of aberrant glycosyla

99 associated with activation of DN T cells in Chagas disease and that CD1d blocking leads to downregul

100 he role of adipocytes in the pathogenesis of Chagas disease and the associated metabolic alterations.

101 e indeterminate or cardiac clinical forms of Chagas disease and whether IL-17 expression can be corre

102 e associated with microthrombus formation in Chagas' disease and a known activator of iPLA2, increase

103 Trypanosoma brucei are parasites that cause Chagas' disease and African sleeping sickness, respectiv

104 diseases such as African sleeping sickness, Chagas' disease and leishmaniasis.

105 Schistosomiasis, malaria, leishmaniasis, Chagas disease, and African sleeping sickness affect hun

106 sue relationship between T. cruzi infection, Chagas disease, and host glucose homeostasis.

107 Trypanosoma cruzi is the causative agent of Chagas disease, and infects 5-8 million people in Latin

108 ich in humans cause African trypanosomiasis, Chagas disease, and leishmaniasis, respectively.

109 kungunya, zika, yellow fever, leishmaniasis, chagas disease, and malaria, with highest incidences in

110 a cruzi ( T. cruzi ), the causative agent of Chagas disease, and the results of structure-activity in

111 al diseases (11 with schistosomiasis, 5 with Chagas' disease, and 10 with cutaneous leishmaniasis), a

112 t in vivo behavior during the acute phase of Chagas disease; and (iii) neither nonspecific toxicity n

113 peutic strategies for the treatment of acute Chagas disease are feasible and that this approach may w

114 goal of delivering a new drug candidate for Chagas disease are reported.

115 Current therapeutic options for Chagas' disease are limited to benznidazole and nifurtim

116 Chagas disease-associated cardiomyopathy is clinically s

117 evidenced by recent microepidemics of acute Chagas disease attributed to the consumption of parasite

118 Trypanosoma cruzi, the etiological agent of Chagas disease, bears primary responsibility for produci

119 tential new drug target for the treatment of Chagas disease but has not been well studied.

120 on, AhR influences the development of murine Chagas disease by modulating ROS production and regulati

121 emic hypertension (SH), rheumatic fever, and Chagas' disease (C'D) are higher in LA.

122 e to another, and present case estimates for Chagas disease came from various sources, including WHO

123 e events described in human and experimental Chagas disease can contribute to, or aggravate, this pat

124 Chagas disease occur annually due to chronic Chagas disease cardiomyopathy (CCC), an inflammatory car

125 Chronic Chagas disease cardiomyopathy, caused by Trypanosoma cru

126 Chagas disease caused by Trypanosoma cruzi is a paradigm

127 Chagas disease, caused by infection with the protozoan p

128 Chagas disease, caused by the eukaryotic (protozoan) par

129 Chagas disease, caused by the parasite Trypanosoma cruzi

130 Chagas disease, caused by the parasite Trypanosoma cruzi

131 Chagas disease, caused by the protozoan parasite Trypano

132 Chagas disease, caused by the protozoan parasite Trypano

133 Chagas disease, caused by the protozoan Trypanosoma cruz

134 Chagas disease, caused by Trypanosoma cruzi parasite, wa

135 Chagas disease, caused by Trypanosoma cruzi, is an impor

136 Chagas' disease, caused by the hemoflagellate protozoan

137 Cardiomyopathy is a serious complication of Chagas' disease, caused by the protozoan parasite Trypan

138 Chagas' disease, caused by the protozoan parasite Trypan

139 Chagas disease causes a severe inflammatory dilated chro

140 IC50 at 11.9 and 17.2 muM against neglected Chagas' disease causing Trypanosoma cruzi, respectively.

141 age with benznidazole to prevent congenital Chagas disease (CCD), as well as the usefulness of polym

142 Chagas disease (CD) affects over 300 000 people in the U

143 of only 2 medications available for treating Chagas disease (CD) and currently the only drug availabl

144 we evaluated the congenital transmission of Chagas disease (CD) in a nonendemic area.

145 rs for Disease Control and Prevention (CDC), Chagas disease (CD) may affect 1.31% of Latin American i

146 linical outcomes of the disease it provokes: Chagas disease (CD).

147 e findings suggest that during the course of Chagas disease, CD8(+) T cells undergo a gradual loss of

148 Chagas disease, characterized by acute myocarditis and c

149 sialidase (TcTS) is a key target protein for Chagas disease chemotherapy.

150 tial to fulfill the urgent need for improved Chagas disease chemotherapy.

151 riate for further development toward an anti-Chagas disease clinical candidate.

152 ecies profile is altered in individuals with Chagas disease compared with healthy controls.

153 Trypanosoma cruzi, the causative agent of Chagas disease, contains exclusively iron-dependent supe

154 As Chagas disease continues to expand beyond tropical and s

155 icular (human African trypanosomiasis (HAT), Chagas disease, cutaneous leishmaniasis, and malaria) ha

156 in toxicity of benznidazole in patients with Chagas disease, determine the serum cytokine profile, an

157 se and conclude with a view of the future of Chagas disease diagnosis, pathogenesis, therapy, and pre

158 Trypanosoma cruzi, the agent of Chagas disease, does not seem to control gene expression

159 Trypanosoma cruzi, the causative agent of Chagas disease, encodes for an alpha-carbonic anhydrase

160 etiologic agent of American trypanosomiasis (Chagas disease), exhibiting IC(50) values in the nanomol

161 man parasite Trypanosoma cruzi, the agent of Chagas' disease, expresses a membrane-bound neuraminidas

162 in the pathogenesis of experimental chronic Chagas disease, favoring inflammation and fibrogenesis.

163 l and regional health and economic burden of Chagas disease from the societal perspective.

164 In vivo tests on the acute phase of Chagas disease gave parasitemia inhibition values twice

165 Each Chagas disease group displayed distinct gene expression

166 Oral transmission of Chagas disease has emerged in unpredictable situations i

167 n the USA (Lyme disease $2.5 billion), where Chagas disease has not been traditionally endemic, sugge

168 costs emanate from the USA and Canada, where Chagas disease has not been traditionally endemic.

169 by Trypanosoma cruzi, the causative agent of Chagas disease, has recently been described, with differ

170 cardiomyopathy, the main clinical problem in Chagas' disease, has been extensively studied but is sti

171 in Trypanosoma cruzi, the causative agent of Chagas' disease, has not been examined well.

172 Preclinical models of Chagas disease have demonstrated that antigen-specific C

173 of Trypanosoma cruzi, the etiologic agent of Chagas disease, have been highly inefficient, and no end

174 ected Trypanosoma cruzi, the causal agent of Chagas disease, implying the existence of evasion or tol

175 substantially ameliorates symptoms of acute Chagas disease in a mouse model with no apparent toxicit

176 We found a 13% point prevalence of Chagas disease in a sample of New York City immigrants w

177 pecies as a means to alleviate the burden of Chagas disease in affected regions.

178 ritic cell-based immunotherapeutic for acute Chagas disease in an attempt to delay or prevent the car

179 INTERPRETATION: Screening for Chagas disease in asymptomatic Latin American adults liv

180 infection, a protozoan parasite that causes Chagas disease in humans.

181 e have been major advances in the control of Chagas disease in most of the countries endemic for this

182 s as means of identifying new drugs to treat Chagas disease in the acute phase with greater activity,

183 , there are approximately 8 million cases of Chagas disease in the southern cone of South America alo

184 r, 300 000 individuals are estimated to have Chagas disease in the United States.

185 the blood of various tetrapods and vector of Chagas' disease in humans, carries in its genome four di

186 e persistence and a chronic illness known as Chagas' disease in humans.

187 several vertebrate hosts is responsible for Chagas' disease in Latin America.

188 zi, the protozoan parasite that causes human Chagas' disease, induces a type I interferon (IFN) (IFN-

189 Trypanosoma cruzi, the agent of Chagas' disease, infects a variety of mammalian cells in

190 Chagas disease is a chronic infection caused by Trypanos

191 Chagas disease is a chronic infection in humans caused b

192 Chagas disease is a deadly infection caused by the proto

193 revent the deadly cardiac pathology in human Chagas disease is a desirable and currently unattained g

194 Chagas disease is a neglected tropical disease caused by

195 Chagas disease is a neglected tropical disease with 6-7

196 American Trypanosomiasis or Chagas disease is a prevalent, neglected and serious deb

197 Chagas disease is a well-known cause of cardiomyopathy i

198 Chagas disease is amongst the ten most important neglect

199 Chagas disease is caused by the intracellular protozoan

200 Chagas disease is caused by the parasite Trypanosoma cru

201 Chagas disease is caused by the protozoan parasite Trypa

202 Chagas disease is caused by the protozoan parasite Trypa

203 Chagas disease is caused by the protozoan Trypanosoma cr

204 Chagas disease is characterised by an acute phase, which

205 Oral transmission of Chagas disease is considered when >1 acute case of febri

206 Chagas disease is currently prevalent in European countr

207 nd mortality in areas of Latin America where Chagas disease is endemic and among infected individuals

208 Chagas disease is endemic in Latin America and an emergi

209 In Latin America, cardiomyopathy caused by Chagas disease is endemic.

210 ful that the epidemiological significance of Chagas disease is in steep decline.

211 The pathological progression of Chagas disease is influenced by the infiltration and tra

212 How the immune response causes Chagas disease is not clear, but during the persistent i

213 Chagas disease is now an active disease in the urban cen

214 oximately 8 million people in Latin America, Chagas disease is now becoming a serious global health p

215 Chagas disease is one of the main public health issues i

216 Chagas disease is one of the major neglected diseases of

217 The economic burden of Chagas disease is similar to or exceeds those of other p

218 Chagas' disease is a zoonosis prevalent in Latin America

219 Chagas' disease is an important cause of cardiomyopathy

220 Chagas' disease is caused by infection with the parasite

221 The severity of Chagas' disease is correlated with persistent parasitism

222 Trypanosoma cruzi infection (which causes Chagas disease) is typically undiagnosed and persists if

223 Trypanosoma cruzi, the etiological agent of Chagas disease, is a protozoan parasite with a complex l

224 infection, which is the etiological agent of Chagas disease, is associated with intense inflammation

225 fection, schistosomiasis, leishmaniasis, and Chagas disease, is being led by nonprofit product develo

226 Trypanosoma cruzi, a parasite that causes Chagas' disease, is endemic in parts of Mexico, South Am

227 olvement of MBL/MASP2-associated pathways in Chagas' disease, it is currently unknown whether MBL pla

228 Trypanosoma cruzi, the causing agent of Chagas disease, leads to an activation of the immune sys

229 s against other protozoal species: T. cruzi (Chagas disease), Leishmania major (cutaneous leishmanias

230 Chagas disease, leishmaniasis and sleeping sickness affe

231 ive agents of human African trypanosomiasis, Chagas disease, leishmaniasis, and malaria, respectively

232 ding malaria, human African trypanosomiasis, Chagas disease, leishmaniasis, filariasis, and schistoso

233 in eastern Burma and vector-borne diseases (Chagas' disease, leishmaniasis, and yellow fever) in Col

234 Whether asymptomatic individuals at risk of Chagas disease living in Europe should be screened and t

235 against cruzain, a thiol protease target for Chagas disease, looking for reversible, competitive inhi

236 with at least three different techniques for Chagas disease, maintained at controlled low temperature

237 cardiac, digestive and asymptomatic) chronic Chagas disease manifestations.

238 Trypanosoma cruzi, the protozoan that causes Chagas' disease, modulates the extracellular matrix netw

239 gest that galectin-3 is strongly involved in Chagas disease, not only in the immune response against

240 Approximately 12000 deaths attributable to Chagas disease occur annually due to chronic Chagas dise

241 OS] in the Treatment of Asymptomatic Chronic Chagas Disease [P05267] [STOP CHAGAS]: NCT01377480).

242 d neurotrophic factor (PDNF) produced by the Chagas' disease parasite Trypanosoma cruzi binds nerve g

243 The Chagas' disease parasite Trypanosoma cruzi commonly infe

244 The Chagas' disease parasite Trypanosoma cruzi elicits a pot

245 The journey of the Chagas' disease parasite Trypanosoma cruzi in the human

246 verall, this work provides new insights into Chagas disease pathogenesis and presents an analytical c

247 >100 years ago, much has been learned about Chagas disease pathogenesis; however, the outcome of T.

248 Prospective observational study where adult Chagas disease patients accepting to receive benznidazol

249 Only a minority of samples from Chagas disease patients possessed antibodies against rLb

250 Similarly, symptomatic acute Chagas' disease patients displayed increased serum conce

251 e in neuropathology, and/or lack thereof, in Chagas' disease patients.

252 The US-based Center of Excellence for Chagas Disease performed an observational study on the s

253 ls with chronic indeterminate (asymptomatic) Chagas' disease potently blocked invasion of Trk-bearing

254 Chagas disease presents an increasing challenge for clin

255 Even with a reduction in Chagas disease prevalence to 0.05% and with large variat

256 ytotoxicity could play a role in determining Chagas disease progression.

257 a neurotransmitter thought to play a role in Chagas' disease progression.

258 Trypanosoma cruzi, the agent of Chagas' disease, promotes neuron survival through recept

259 ted therapeutic options to prevent and treat Chagas disease put 8 million people infected with T. cru

260 mended for all cases of acute and congenital Chagas disease, reactivated infection, and chronic T cru

261 role of autoimmunity in the pathogenesis of Chagas disease remain unanswered, the development of aut

262 Patients with Chagas' disease remain asymptomatic for many years, pres

263 ver, occurrence of primary RV dysfunction in Chagas disease remains controversial.

264 Trypanosoma cruzi, the etiologic agent of Chagas disease, resists extreme fluctuations in osmolari

265 panosomes are causative agents of Nagana and Chagas disease respectively, and speciated about 300 mil

266 hose with the indeterminate clinical form of Chagas disease, respectively.

267 investigated include malaria, leishmaniasis, Chagas' disease, roundworm, whipworm, pinworm, Chinese l

268 In chronic Chagas disease, RV systolic dysfunction is more commonly

269 rformed an economic evaluation of systematic Chagas disease screening of the Latin American populatio

270 The patient newly diagnosed with Chagas disease should undergo a medical history, physica

271 A potential drug target for treatment of Chagas disease, sterol 14alpha-demethylase from Trypanos

272 since the 1990s, but symptomatic congenital Chagas disease still represents a significant, albeit ch

273 iomyocytes, as well as in the mouse model of Chagas disease, supporting the involvement of TcAPx-CcP

274 eir partnership in the immunopathogenesis of Chagas disease, the chronic infection caused by the intr

275 Trypanosoma cruzi, the parasite that causes Chagas disease, the elongated, flagellated trypomastigot

276 azole are the front-line drugs used to treat Chagas disease, the most important parasitic infection i

277 te the possibility of using RDTs to diagnose Chagas disease, thereby decreasing the time to treatment

278 or Trypanosoma cruzi, the causative agent of Chagas' disease, to escape from the host immune system a

279 a cruzi parasite is the etiological agent of Chagas disease, treatment is still plagued by limited ef

280 ganisms, including the etiological agents of Chagas disease (Trypanosoma cruzi) and African sleeping

281 date tipifarnib kills the causative agent of Chagas disease, Trypanosoma cruzi, by blocking ergostero

282 of genomic DNA from the parasite that causes Chagas disease, Trypanosoma cruzi, directly in whole, un

283 e: Trypanosoma cruzi, the causative agent of Chagas disease; Trypanosoma brucei, the causative agent

284 study RV systolic function in patients with Chagas disease using cardiac magnetic resonance.

285 o cross-sectional data of infestation by the Chagas disease vector Triatoma infestans in the city of

286 ling the position of major clades (e.g., the Chagas disease vectors Triatominae).

287 against both the acute and chronic phases of Chagas disease was considered.

288 Chagas disease was diagnosed in 25 (19%) patients.

289 that the sylvatic (animal-infected) cycle of Chagas' disease was probably well established at the tim

290 with Rhodnius prolixus, the insect vector of Chagas disease, we show that an ovary dual oxidase (Duox

291 To discover new possible therapies for Chagas' disease, we evaluated against all Trypanosoma cr

292 ne bug Rhodnius prolixus is a main vector of Chagas disease, which affects several million people, mo

293 Trypanosoma cruzi (TC) causes Chagas disease, which in its chronic stage remains incur

294 Chagas disease, which was once thought to be confined to

295 study included 158 individuals with chronic Chagas disease who underwent cardiac magnetic resonance.

296 an heart samples obtained from subjects with Chagas disease who underwent heart transplantation showe

297 cellular experiments, cures the experimental Chagas disease with 100% efficacy, and suppresses viscer

298 HF) with reduced ejection fraction caused by Chagas' disease, with other etiologies, in the era of mo

299 ical aspects of the disease, such as chronic Chagas disease without detectable cardiac pathology, as

300 soma cruzi leads to the development of human Chagas' disease, yet the functional contributions of the